Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., executed a transaction on June 1, 2026, involving the sale of company stock valued at $110,601. The disposal comprised 4,653 shares of common stock, sold at an individual price point of $23.77 per share.
This reported transaction takes place in a market context where the shares are trading at $22.86. This current price represents a notable decline of 46% when compared to the 52-week high of $42.37. Despite this recent depreciation, some analysis suggests that the stock may still be considered undervalued at its current levels.
Following this specific sale, Mr. Horn maintains a direct holding of 105,689 shares of Ultragenyx Pharmaceutical common stock. This total ownership figure incorporates previously reported amounts of common stock underlying restricted stock units (RSUs) that were granted to him and are subject to specified vesting conditions.
Recent Financial Performance and Guidance
In other financial developments, Ultragenyx Pharmaceutical Inc. reported a net loss for the first quarter of 2026 amounting to $1.84 per share. This figure fell short of what analysts had anticipated, as expectations projected a loss of $1.46 per share. Furthermore, the company's revenue also failed to meet forecasts, reporting $136 million against an expected benchmark of $160.69 million.
Despite these reported financial misses for the quarter, Ultragenyx did reaffirm its full-year revenue guidance, providing some stability regarding its annual financial outlook. The company's current profitability profile shows a negative gross profit margin of 28% over the last twelve months.
Analyst Actions and Corporate Governance
On the analyst side, Cantor Fitzgerald recently raised its price target for Ultragenyx shares. The firm increased its target from $84 to $96 while maintaining an Overweight rating. This adjustment in valuation was specifically attributed to growing confidence surrounding GTX-102, a therapeutic agent designed for Angelman syndrome, following extensive research efforts.
Corporate governance saw activity at the company's annual meeting. During this meeting, shareholders approved the election of three Class I directors and several key corporate proposals. The individuals elected to the board of directors include Emil D. Kakkis, M.D., Ph.D., Shehnaaz Suliman, M.D., and Daniel G. Welch. Each of these newly elected members is scheduled to serve until the 2029 annual meeting or until successors are appointed.
Key Insights and Market Context
The combination of executive transactions, recent quarterly losses, and positive research adjustments highlights significant corporate activities and strategic shifts within Ultragenyx. The company remains among a group of over 1,400 US equities that are covered by comprehensive Pro Research Reports, which aim to translate complex financial data into actionable intelligence for investors.
The reported transactions and corporate actions provide a detailed look at the company's current standing. While recent losses were noted in Q1 2026, reaffirmation of full-year revenue guidance suggests management confidence in achieving annual targets, despite the stock trading significantly below its historical high. The positive rating update from Cantor Fitzgerald, tied to GTX-102 progress, points toward potential future valuation support.Key Takeaways for Investors
- Executive Activity: CFO Howard Horn sold shares on June 1, 2026. His remaining direct holdings total 105,689 common shares.
- Financial Performance Mix: The company reported Q1 2026 net losses and missed revenue forecasts ($136 million vs $160.69 million expected). However, it reaffirmed full-year revenue guidance.
- Positive Analyst Viewpoint: Cantor Fitzgerald raised the price target for shares to $96 (from $84) with an Overweight rating, citing progress on GTX-102 treatment development.